A novel necrosis inhibitor, LC28-0126, is expected to have a cellular protective effect from ischaemic reperfusion injury in acute myocardial infarction. The objective of this study was to investigate the safety, tolerability and pharmacokinetics of LC28-0126 after a single intravenous administration in healthy male subjects.
Introduction
Acute myocardial infarction (AMI) is a major health care and economic problem from clinical, psychological and social points of view [3] . In the United States, more than 1.5 million new cases of AMI are diagnosed each year; in Korea in 2007, the incidence rate for AMI was 91.8 per 100 000 persons, more than double the rate in 1997 [4, 5] .
The mortality rates of AMI have decreased through the introduction of coronary care units in the 1960s, pharmacological reperfusion therapy in the 1980s, and the widespread application of catheter-based interventions in the 1990s [3] . The introduction of reperfusion therapy with coronary angioplasty or thrombolysis resulted in a reduction in the size of the myocardium affected by ischaemia [6] [7] [8] . However, reperfusion paradoxically causes myocardial injury in the form of reperfusion injury, myocardial stunning, reperfusion arrhythmias and endothelial injury [9, 10] .
Necrosis is the main mechanism of apoptosis in pathological conditions and is a major factor in the pathogenesis of ischaemia and reperfusion injury. After the phenomenon of 'ischaemic preconditioning' was reported in 1986 [11] , these phenomena of myocardial 'conditioning' have provided potential tools for attenuating ischaemia-reperfusion injury [11, 12] . Many studies of the mechanisms underlying protection have led to the discovery of several pharmacological agents that can harness these protective mechanisms and be used as adjuncts to standard reperfusion therapy to limit reperfusion injury in patients with AMI [13] .
The novel small-molecule necrosis inhibitor LC28-0126, a mitochondria-targeted reactive oxygen species (ROS) scavenger, exerts dual anti-inflammatory and anti-necrotic functions [14] [15] [16] . Furthermore, LC28-0126 ameliorates the pathophysiology of oxidative stress-induced injury by inhibiting high-mobility group box 1 (HMGB1) release, mitochondrial NADPH oxidase complex activity, mitochondrial calcium uniporter activity and mitochondrial permeability transition pore opening [16] [17] [18] . In terms of necrosis pathology, we at first focused on developing a cardioprotective agent using a necrosis inhibitor LC28-0126 for ST-segment elevation myocardial infarction patients with AMI. It is well known that the necrosis of cardiomyocytes is a decisive celldeath mechanism influencing cardiac infarct mass, which is the main pathophysiology of ischaemia-reperfusion injury [19] . The inhibitory effect on cell necrosis exerted by LC28-0126 has been observed in both in vitro and in vivo rat models [19] . Accordingly, LC28-0126 is expected to have a cellular protective effect, including in the context of protecting cardiomyocytes from ischaemic reperfusion injury in AMI and was found to have a minimal effective dose (MED) of 0.3 mg kg À1 . In addition, LC28-0126 showed a wide safety margin with tolerance up to 550-fold and 360-fold of the MED in mice and beagle dogs, respectively, based on single and repeated dosing regimens in nonclinical toxicology studies.
The objective of this first-in-human clinical trial was to investigate the safety/tolerability and pharmacokinetic (PK) characteristics of a single intravenous injection of LC28-0126 in healthy male subjects.
Methods

Study participants
Healthy male Korean subjects between the ages of 20 and 45 years, both inclusive, and with a body mass index (BMI) in the range of 18-27 kg m À2 and a body weight in the range of 55-90 kg were enrolled in this study. Written, informed consent was obtained from all subjects prior to any study procedures. Prior to enrolment, subjects were examined to confirm that they were of sound physical and mental health. Subjects who consumed any medicine, food, or beverage that is known to influence drug metabolism within 2 months prior to the study initiation were excluded from the study.
Study design
The study (ClinicalTrials.gov Identifier: NCT01737424) protocol was reviewed and approved by the Ministry of Food and Drug Safety of Korea (MFDS), as well as the institutional review board of Seoul National University Hospital (SNUH, Seoul, South Korea). All study procedures were conducted in accordance with the Declaration of Helsinki and Korean Good Clinical Practices. The study followed a dose-block-randomized, doubleblind, placebo-controlled, single ascending dose design with two separate cohorts, cohort 1 and 2 ( Figure 1 ). In cohort 1, the study drug was intravenously infused at doses of 3, 10, 25, 50, 100 or 200 mg for 30 min (LC28-0126 group, n = 3; and placebo group, n = 1 in each dose group). In cohort 2, the study drug was infused for 5 min at doses of 0.3, 1, 3, 10, 25, 50, 100 or 200 mg, which was expected to be used in clinical practice (LC28-0126 group, n = 6; and placebo group, n = 2 in each dose group). All reported adverse events (AEs) and examinations which were conducted to assess the safety and tolerability of LC28-0126 among the study subjects were reviewed by investigators to determine the safety profile. Based on this review, the principal investigator decided the initiation of next cohort (Figure 1 ). The subjects were randomly assigned to receive a single dose of LC28-0126 or placebo. Furthermore, an interim analysis to assess the tolerability and PK characteristics was conducted in each dose group. Subsequently, the protocol, including dose and PK evaluation methods, was amended according to the interim analysis ( Figure 1) .
The no-observed-adverse-effect-level (NOAEL) in mice, which is the most sensitive species, was 40 mg kg À1 ; this dose corresponded to a maximum recommended starting dose of 9.6 mg in 60-kg healthy male adults, whereas preclinical study determined that the MED of LC28-0126 in a MI mouse model was 0.3 mg kg À1 , which corresponds to a human equivalent dose (in a 60-kg adult) of 3 mg. Based on these and considering the smaller of NOAEL and MED, 3 mg was selected for the starting dose. The efficacy dose of LC28-0126 in humans was estimated by using various animal models: the liver ischaemia-induced beagle model demonstrated an inhibitory effect of LC28-0126 on changes in alanine transaminase activity at a dose of 1.5 mg kg À1 (HED, 49 mg), and in a beagle model of liver ischaemia-reperfusion, the MED was 4.5 mg kg À1 (HED, 146 mg). Based on these estimated efficacy doses in humans, we selected 200 mg as the highest dose in this study. The subjects were admitted to the SNUH Clinical Trial Centre 1 day prior to dose administration and the subjects received the study drug intravenously using an infusion pump. The subjects fasted for 4 h after being dosed, and water was prohibited during the first 2 h after administration.
Blood samples (5 ml each) were taken to determine plasma LC28-0126 concentrations from predose to 48 h postdose (3, 
Figure 1
Study flow Pharmacokinetics and safety of a single dose of LC28-0126 however, after the protocol was amended, additional blood sampling points were obtained at 72, 96, 120 and 144 h after LC28-0126 administration in both cohorts, thus increasing the number of samples per subject to 22. The blood samples were collected into tubes containing sodium heparin and centrifuged at 1920 g for 10 min at 4°C. The separated plasma was mixed with 0.005% ascorbic acid (plasma:ascorbic acid = 1:1), and the mixed plasma was kept in a freezer below À70°C until being analysed.
Urine samples were collected from all subjects before dosing and at subsequent intervals after drug administration. For subjects in cohorts 1 and 2 who were administered 3, 10 or 25 mg LC28-0126, urine was obtained between 0-6 h, 6-12 h, 12-24 h and 24-48 h after dosing (five intervals per subject). All other subjects (50, 100 and 200 mg dose groups in cohort 1 and 0.3, 1, 50, 100 and 200 mg dose groups in cohort 2) had their urine collected between 0-6 h, 6-12 h, 12-24 h, 24-48 h and 48-72 h after dosing (six intervals per subject). At the end of each urine collection interval, urine volume was recorded (volume was measured using weight; 1 g of urine was converted to 1 ml), and the collected urine was mixed with 0.005% ascorbic acid (urine:ascorbic acid = 1:1). The mixed urine was kept in a freezer below À70°C until being analysed.
Safety/tolerability assessments
All AEs were recorded on investigators' questionnaires or subjects' spontaneous reports. All AEs were assessed by the investigators with respect to severity, course, outcome, seriousness, and relationship to the study drug and were recorded regardless of the suspected relationship to the study drug. Physical examinations, vital-sign measurements, 12-lead electrocardiograms (ECGs), laboratory testing (haematology, clinical chemistry, coagulation, and thyroid function tests and urinalysis) were performed at predefined, regular intervals throughout the studies. Additionally, CK-MB, d-dimer and troponin I tests were performed to detect or screen for any crystallization and subsequent microembolization during infusion. The clinical laboratory tests were performed by the Department of Laboratory Medicine at SNUH, and quality control was ensured according to the internal standard operating procedures of SNUH.
Determination of LC28-0126 levels
Plasma and urine concentrations of LC28-0126 were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Plasma and urine sample were quenched with 0.005% ascorbic acid (1/1, v/v). The standards for LC28-0126 and the internal standard (IS) D 5 -LC28-0126 were provided by LG Life Sciences, Ltd. (Seoul, Korea). The assay was linear in the concentration ranges of 1-2000 ng ml À1 and 0.5-1000 ng ml À1 in the plasma and urine analyses, respectively. The lower limit of quantification (LLOQ) of plasma was 1.0 ng ml À1 , and that of urine was 0.5 ng ml À1 . Amber tubes were used during all determination procedures. Aliquots (50 μl) of each standard, quality control and sample fluid were separately mixed with 100 μl of 20 ng ml À1 IS solution to precipitate proteins. The mixture was vortexed and centrifuged at 20 817 × g for 5 min at 4°C. The supernatant (50 μl) was removed and mixed with water (50 μl). Then, 1 μl of this mixture was injected into an HPLC system (Nanospace SI-2; Shiseido Fine Chemicals, Tokyo, Japan) and analysed by LC-MS/MS under the conditions below. Chromatographic separation was conducted using a Luna C8 column (3 μm, 30 × 2.0 mm, Phenomenex, Torrance, CA, US) while the column temperature was maintained at 30°C. The mobile phase consisted of acetonitrile and water, and the flow rate was maintained at 0.4 ml min À1 .
Detection was performed by an AB Sciex API 4000 (Applied Biosystems/MDS-Sciex, Toronto, Canada) mass spectrometer configured with electrospray ionization in the positiveion mode. The correlation coefficient (r) of all plasma sample batches was more than 0.998, the imprecision of back-calculated concentration was less than 6.6%, and the accuracy was between 98.6% and 101.7%. The correlation coefficient of all urine sample batches was more than 0.998, the imprecision of back-calculated concentration was less than 8.9%, and the accuracy was between 96.5% and 101.7%. Full details of validation results of plasma and urine LC28-0126 determination can be found in the Supporting Information.
Pharmacokinetics assessments
The PK analysis of LC28-0146 was conducted by the noncompartmental method using WinNonlin (Version 6.3.0., Certara, Princeton, NJ, USA). The actual times at which the blood and urine samples were obtained were used in the PK analysis. If the concentration in blood was below LLOQ, this concentration was treated as zero before time to maximal concentration (t max ) and as missing data after t max . If the concentration in urine was below LLOQ, it was treated as zero.
The maximum plasma concentration of LC28-0126 (C max ) and t max were directly obtained from the observed data. The area under the plasma concentration curve extrapolated to infinity (AUC inf ) and the area under the plasma concentration curve from time 0 to the last detectable time point (AUC last ) were estimated by the linear-up/log-down rule. Clearance (CL) was calculated by dividing the infused dosage by AUC inf , and the renal clearance (CL R ) was calculated by dividing the total amount excreted in the urine (A e ) by AUC inf . The fractional amount excreted in the urine (f e ) was calculated by dividing A e by the infused dosage. The terminal elimination rate constant (λ z ) was estimated by a linear regression of the logarithmic-linear decline of the plasma concentration-time curve. The terminal elimination half-life (t 1/2 ) was calculated as ln(2)/λ z . Dose-normalized C max and AUC last were calculated as the corresponding PK parameters divided by the administered dose.
Statistical analysis
The statistical analysis was carried out using SAS (Version 9.4; SAS Institute, Cary, NC, US). The arithmetic means and standard deviations (SDs), medians, and minimum and maximum values were calculated for continuous data, and the absolute and relative frequencies were calculated for categorical data. ANOVA was performed on dose-normalized C max and AUC inf values. To demonstrate dose-independent linear PK properties, linear regressions between dose and C max or Table 1 Demographic characteristics The values are presented as the mean ± SD (min -max). BMI, body mass index; SD, standard deviation.
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AUC inf and between logarithm-transformed dose and logarithm-transformed C max or logarithm-transformed AUC inf were performed.
Results
Study population
A total of 24 subjects in cohort 1 and 65 subjects in cohort 2 were enrolled in each dose group ( , respectively. Taken together, the subject randomization was deemed to be statistically appropriate. All study subjects were Korean males. All subjects were included in the safety population and were used for the safety analyses.
Safety/tolerability
A total of 25 AEs were reported in 22 subjects. Of the 22 subjects who experienced AEs, 17 subjects received LC28-0126 (Table 2) . In cohort 1, there were 3 AEs only in the 200 mg dose group, and out of 12 treatment-emergent AEs (TEAEs) in cohort 2, there were 10 in the 50, 100 and 200 mg dose groups. All AEs that emerged during the study were mild, except for the two moderate severity cases. One subject in the 100 mg dose group of cohort 2 showed increased creatine phosphokinase (36 790 IU/l, corresponding to Grade 4 AE based on the CTCAE version 4.03) after strenuous physical activities. As this AE was asymptomatic, the subject was monitored without any related management until the levels were reduced, which indicated a full recovery within five days. And, one subject in cohort 2 who complained of hearing loss in the left ear after administration of 200 mg of LC28-0126 was diagnosed with sudden sensorineural hearing loss (SSHL), and a relationship to the drug could not be ruled out. After a 4-week treatment with methylprednisolone, the overall symptoms disappeared. The subject was withdrawn from the study at the discretion of the investigators. All AEs were spontaneously resolved except one case of sudden hearing loss. The most common AE was pain at the administration site. Mild pain at the administration site was reported during administration of the 200 mg dose by two subjects in cohort 1 and by three subjects in cohort 2. This pain at the administration site disappeared after the infusion of the investigational drug was completed. The logistic regression revealed a dose-AE relationship in cohort 2 (P = 0.020, odds ratio = 1.018).
Except for the two subjects who reported sudden hearing loss and who showed increased creatine phosphokinase, no clinically significant changes in or abnormalities of vital signs, ECGs, laboratory tests or physical examinations were observed in the subjects. And, there were no clinically significant changes in cardiac enzyme (Table 3) .
Pharmacokinetic properties
The graphs of mean plasma LC28-0126 concentration over time after a 30-or 5-min intravenous infusion of LC28-0126 are shown in Figure 2 . The PK parameters of LC28-0126 of Table 2 Summary of LC28-0126 related adverse events Administration site pain (during drug infusion)
Catheter site haematoma
Sudden sensorineural hearing loss Table 3 Cardiac enzyme levels before and after LC28-0126 administration The values are presented as the mean ± SD. Reference range: CK-MB < 6.3 ng ml
À1
; d-dimer < 0.39 μg ml
; and troponin I < 0.06 ng ml
Pharmacokinetics and safety of a single dose of LC28-0126 the two cohorts are presented in Tables 4 and 5 . The PKs of the investigational drug appeared to follow a multiple-compartment model after administration. In cohort 1, the median t max of LC28-0126 was 20 min from infusion start, before the end of the infusion, and that of cohort 2 was 5 min from infusion start, at the end of the infusion. The range of mean t 1/2 was 27.3-45.4 h, and the range of mean CL was 2.0-3.6 l h À1 in cohorts 1 and 2. Overall, the f e of LC28-0126 during 48 or 72 h after administration was below 5% (Tables 4 and 5 ). The dose linearity of C max and AUC inf of LC28-0126 was tested in cohort 2. Regarding the dose linearity of the PK parameters, we observed that while there were no significant differences in AUC inf /Dose (P = 0.052), there were significant differences in C max /Dose (P = 0.016) among all eight dose groups in cohort 2. The power model exponent for C max and AUC inf were 0.92 and 1.01, respectively, and the corresponding confidence intervals were 0.88-0.96 and 0.96-1.05, respectively, among all dose groups (Figure 3) . Regarding the wide range of study drug dose, we conducted an additional linearity assessment of the dose groups of 1, 3 and 10 mg in cohort 2, which are expected to be used in a clinical setting and examined in Phase II clinical trials. The power model exponents for C max and AUC inf were 0.95 and 0.98, respectively. The corresponding confidence intervals were 0.80-1.10 and 0.87-1.09, respectively. These suggested that the relationships between C max and AUC inf and dose were linear in the 1, 3 and 10 mg dose groups. And the systemic exposure of LC28-0126 tends to be increased in a dose-proportional manner in the dose range of 0.3-200 mg.
Discussion
The goals of this first-in-human study were to determine the PK characteristics and safety/tolerability of LC28-0126 after a single dose of LC28-0126 in healthy Korean male subjects.
The results showed that the PK of LC28-0126 is explainable by a multiple-compartment model rather than a singlecompartment model. Regarding disposition in the early phase, it is likely that LC28-0126 is rapidly distributed to tissues and cells in humans. From the preclinical trial of LC28-0126 in rats, the tissue/plasma ratio of LC28-0126 was 13.48 from the liver, and the tissue/plasma ratios from the pancreas, kidneys, adipose tissue, heart and lungs ranged from 2.14 to 5.16. Furthermore, more than half of LC28-0126 in systemic circulation was distributed and eliminated within 30 min (cohort 1: 53%, cohort 2: 76%). The excessive production of ROS in the early minutes of reperfusion is known to trigger mitochondrial permeability transition pore opening [20] [21] [22] . Garcia-Dorado et al. suggested that cell injury occurs rapidly due to necrosis in the first few minutes of reperfusion, and recent studies have shown that myocardial ROS generation peaks within the first 5 min of reperfusion [23, 24] . In this context, the exposure of LC28-0126 is expected to be sufficient to exert pharmacological effects between the initiation of drug infusion and the end of percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. In addition, mean clearance in the 25 mg dose groups in both cohorts appeared to be higher than that in the other dose groups (Tables 4 and 5 ). However, we did not notice any unique outliers and we could not identify a reason for this and it was thought to be due to variability.
The safety results from this study demonstrate that 5-or 30-min intravenous infusions of a single dose of LC28-0126 at doses ranging from 0.3 to 200 mg in Korean healthy subjects were well tolerated. In this study, there was a case of moderate SSHL in cohort 2, which was resolved after a 4-week treatment. The causes of SSHL are probably multifactorial, but various aetiological theories have been proposed, and several medicines are commonly associated with ototoxicity [25] [26] [27] . While currently unclear, LC28-0126 could potentially influence the clinical course of SSHL. Although there are several debates on the pathogenesis of SSHL, further investigation into the effect of LC28-0126 on auditory function Table 4 Summary of pharmacokinetic parameters after a 30-min intravenous infusion of LC28-0126 (cohort 1) Table 5 Summary of pharmacokinetic parameters after a 5-min intravenous infusion of LC28-0126 (cohort 2) Pharmacokinetics and safety of a single dose of LC28-0126 is warranted. Furthermore, mild pain at the administration site was reported by two subjects in cohort 1 and by three subjects in cohort 2 in the 200 mg group; this pain disappeared after the completion of the infusion. We assume that this pain during infusion results from a chemical property of LC28-0126. The study drug is acidic, and the prepared 200 mg dose of LC28-0126 for infusion had a pH of 2.7. As the target doses of the Phase II study in patients with ST-segment elevation myocardial infarction are 1, 3 and 10 mg, it is not likely that 200 mg of LC28-0126 will be used in a clinical setting. However, improving the physicochemical properties of LC28-0126 is warranted and planning for evaluation of pain in administration site for further clinical trials of more than 100 mg of LC28-0126 is also warranted. In cohort 1, AEs were observed only in the 200 mg dose group (three cases), and 10 out of the 12 cases of TEAEs in cohort 2 were observed in the 50, 100 and 200 mg dose groups. As such, the administration of 1, 3 and 10 mg of LC28-0126 in a clinical setting is anticipated to be safe; a Phase II clinical trial is underway with 1, 3 and 10 mg dose groups. The prediction of human PKs from preclinical data remains an important point in the drug development process to minimize risk to participants and to develop a proper study design, leading to better results of first-in-human studies. Regarding the protocol development for this firstin-human clinical trial, there was limited PK information, and we could only depend on animal data from the preclinical research and such methods as allometric scaling. From the differences between humans and other animals, such as rats, beagles and monkeys, allometric scaling may yield altered rates of compound metabolism and even produce different metabolite patterns [28] . To overcome these limitations of allometric scaling, the appropriate use of an interim analysis is warranted for first-in-human clinical trials. From the planned interim PK analyses of the 3, 10 and 25 mg dose groups in cohorts 1 and 2, LC28-0126 was confirmed to have an unexpectedly long half-life and an unexpected exposure. To fully characterize the elimination phase, the protocol was amended to increase the follow-up time period after dosing from 48 h to 144 h. Furthermore, the interim PK analysis showed a greater drug exposure than expected; thus, the 0.3 and 1 mg dose groups were added. This amended protocol was effective for the 0.3, 1, 50, 100 and 200 mg groups, and we observed the full PK profiles of LC28-0126 from the interim analysis and the protocol amendment.
In conclusion, this study demonstrated that LC28-0126 doses from 0.3 to 200 mg were safe and well tolerated in healthy subjects. Systemic exposures of LC28-0126 were linear and dose proportional following the intravenous administration of single doses from 1 to 10 mg and exposure tends to be increased in a dose-proportional manner in the dose range of 0.3-200 mg. However, this is a result from the firstin-human clinical trial, and additional assessments regarding the safety, tolerability and effects of LC28-0126 are required from further studies.
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Figure 3
Relationship between individual (A) C max or (B) AUC inf and dose following 5 min intravenous LC28-0126 administration (cohort 2)
